Nattokinase is an oral dietary supplement containing a protein-splitting enzyme from fermented soybeans used to support healthy blood pressure and blood flow. Standard daily doses modestly lower blood pressure in adults with elevated blood pressure, but do not slow neck artery thickening or improve cholesterol when blood pressure is normal. Higher-dose artery-plaque findings remain unconfirmed, and bleeding risks require verified, vitamin K-free extracts without blood-thinning medications. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Seated Resting Blood Pressure | <120/80 mmHg (standard reference range) | Expected-change efficacy marker (and safety check for hypotension <90/60 mmHg) |
| Activated Partial Thromboplastin Time (aPTT) and Prothrombin Time / INR (PT/INR) | 25–35 seconds for aPTT; 0.8–1.1 for INR (standard reference range) | Safety check to rule out supratherapeutic anticoagulation (and acute pharmacodynamic marker) |
| Plasma Fibrinogen and Coagulation Factor VIII Activity | 200–400 mg/dL for fibrinogen; 50%–150% for factor VIII (standard reference range) | Expected-change marker of fibrinolytic and anticoagulant response |
| Fasting Lipid Panel (LDL Cholesterol, HDL Cholesterol, Total Cholesterol) and Fasting Glucose | <100 mg/dL for LDL, ≥40 mg/dL (men) or ≥50 mg/dL (women) for HDL, <200 mg/dL for total cholesterol; 70–99 mg/dL for fasting glucose (standard reference range) | Safety check for short-term lipid or glucose shifts and expected-change efficacy marker at ≥6,000 FU/day |
| Carotid Duplex Ultrasound (IMT and Plaque Area) | No established target; track stabilization or regression from individual baseline | Expected-change efficacy marker when targeting subclinical atherosclerosis with high doses |
Cadence: Baseline testing before initiation; seated home blood pressure weekly for 8 weeks then monthly; coagulation markers at 4 to 8 weeks (when using >2,000 FU/day); fasting lipids and glucose at 3 to 6 months; carotid duplex ultrasound every 6 to 12 months.